当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2018年, 第18卷, 第4期, 第241-246页
标题:
百草枯致肺纤维化动物模型、发病机制及抗纤维化治疗进展
DOI:
10.5428/pcar20180401
作者:
1. 李莎(湖南省人民医院药学部 长沙 410005 musha1220@outlook.com)
2. 刘文(湖南省人民医院药学部 长沙 410005 Liuwen0917@outlook.com)
摘要:
摘要  百草枯中毒致肺纤维化的发生是导致患者死亡的重要原因,也是目前国内外研究的热点和难点。各项研究显示在百草枯动物模型中出现比较典型的肺纤维化时间大约为14~28 d,而最新的研究也并未完全阐明其中毒机制,最主要的解释是肺泡细胞对百草枯具有主动摄取和蓄积特性,且百草枯本身为一电子受体,作用于细胞内的氧化还原反应,生成大量的活性自由基,导致细胞因子网络的紊乱、蛋白酶失衡、线粒体功能障碍,从而促进纤维化的发生与发展。目前,抗纤维化治疗研究主要集中在中草药,且尚处于实验性阶段,缺乏临床数据支持。因此,本文通过综述百草枯致肺纤维化最新的动物模型、发病机制以及治疗方案,以期为百草枯中毒的研究和治疗提供参考。
欢迎阅读《药学服务与研究》!您是该文第 237 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 李莎,刘文. 百草枯致肺纤维化动物模型、发病机制及抗纤维化治疗进展[J]. 药学服务与研究. 2018; 18(4): 241-246.
英文著录格式 LI Sha,LIU Wen. Advances in animal model,pathogenesis and anti-fibrosis treatment of pulmonary fibrosis induced by paraquat[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 241-246.
参考文献:
1. HONG GuangLiang, CAI QiQi, TAN JiaPing, et al. Mifepristone-inducible recombinant adenovirus attenuates paraquat-induced lung injury in rats[J]. Hum Exp Toxicol, 2015, 34(1):32-43.
2. LIU TianJu, De Los Santos F G, Phan S H. The bleomycin model of pulmonary fibrosis[J]. Methods Mol Biol, 2017, 1627:27-42.
3. JIANG YinSong, MA YuYing, WANG ZhanQing, et al. Therapeutic effects of smecta or smectite powder on rats with paraquat toxication[J]. World J Emerg Med, 2013, 4(2):144-150.
4. XU YiHeng, TAI WenLin, QU XiaoYuan, et al. Rapamycin protects against paraquat-induced pulmonary fibrosis: activation of Nrf2 signaling pathway[J]. Biochem Biophys Res Commun, 2017, 490(2):535540.
5. XU XiaoLi, WANG Wei, SONG ZuJun, et al. Imaging in detecting sites of pulmonary fibrosis induced by paraquat[J]. World J Emerg Med, 2011, 2(1):45-49.
6. Malekinejad H, Mehrabi M, Khoramjouy M,et al. Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors[J]. Eur J Pharmacol, 2013, 720(1-3):294-302.
7. Tomita M, Okuyama T, Katsuyama H, et al. Mouse model of paraquat-poisoned lungs and its gene expression profile[J]. Toxicology, 2007, 231(2-3):200-209.
8. Dinis-Oliveira R J, Duarte J A, Sánchez-Navarro A, et al. Paraquat poisoning: mechanisms of lung toxicity, clinical features, and treatment[J]. Crit Rev Toxicol, 2008, 38(1):13-71.
9. SUN Bin, CHEN YuGuo. Advances in the mechanism of paraquat-induced pulmonary injury[J]. Eur Rev Med Pharmacol Sci, 2016, 20(8):1597-1602.
10. LIU ShuLin, LIU Kan, SUN Qiang, et al. Consumption of hydrogen water reduces paraquat-induced acute lung injury in rats[J]. J Biomed Biotechnol, 2011:305086. doi: 10.1155/2011/305086.
11. Knudsen L, Ruppert C, Ochs M. Tissue remodelling in pulmonary fibrosis[J]. Cell Tissue Res, 2017, 367(3):607-626.
12. Mezzano V, Cabrera D, Vial C, et al. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-β and CTGF/CCN2[J]. J Cell Commun Signal, 2007, 1(3-4):205-217.
13. ZHAO Feng, SHI DanYang, LI TieGang, et al. Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro[J]. Clin Exp Pharmacol Physiol, 2015, 42:988-998.
14. Amirshahrokhi K, Khalili A R. Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators[J]. Cytokine, 2016, 88:144-153.
15. CHEN Tong, WANG RuoNing, JIANG WenJiang, et al. Protective effect of astragaloside Ⅳ against paraquat-induced lung injury in mice by suppressing rho signaling[J]. Inflammation, 2016, 39(1):483-492.
16. Amirshahrokhi K. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice[J]. Int Immunopharmacol, 2013, 17(2):210-215.
17. Rasooli R, Pourgholamhosein F, Kamali Y, et al. Combination therapy with pirfenidone plus prednisolone ameliorates paraquat-induced pulmonary fibrosis[J]. Inflammation, 2018,41(1):134-142.
18. Wójcik-Pszczola K, Jakiela B, Plutecka H, et al. Connective tissue growth factor regulates transition of primary bronchial fibroblasts to myofibroblasts in asthmatic subjects[J]. Cytokine, 2018,102:187-190.
19. Mishra D K, Srivastava P, Sharma A, et al. Translationally controlled tumor protein (TCTP) is required for TGF-β1 induced epithelial to mesenchymal transition and influences cytoskeletal reorganization[J]. Biochim Biophys Acta,2018,1865(1):67-75.
20. Fujimoto H, D’Alessandro-Gabazza C N, Palanki M S S, et al. Inhibition of nuclear factor-κB in T cells suppresses lung fibrosis[J].Am J Respir Crit Care Med,2007, 176:1251-1260.
21. SUN Xia, CHEN ErJun, DONG Rui, et al. Nuclear factor (NF)-κB p65 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β[J]. Life Sci, 2015, 122:8-14.
22. Ishibuchi H, Abe M, Yokoyama Y, et al. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis[J]. Exp Dermatol, 2010, 19(8):e111-e116.
23. HUANG Min, YANG HuiFang, ZHU LingQin,et al. Inhibition of connective tissue growth factor attenuates paraquat-induced lung fibrosis in a human MRC-5 cell line[J]. Environ Toxicol, 2016, 31(11):1620-1626.
24. Rasooli R, Rajaian H, Pardakhty A, et al. Preference of aerosolized pirfenidone to oral intake: an experimental model of pulmonary fibrosis by paraquat[J]. J Aerosol Med Pulm Drug Deliv, 2018,31(1):25-32.
25. Rajasekaran S, Vaz M, Reddy S P. Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo[J]. Plos One, 2012, 7(7):e41611.
26. WANG BoLiang, TU YanYang, FU JianFang, et al. Unbalanced MMP/TIMP-1 expression during the development of experimental pulmonary fibrosis with acute paraquat poisoning[J]. Mol Med Rep, 2011, 4(2):243-248.
27. CHEN Yan, NIE YiChu, LUO YuLong, et al. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice[J]. Food Chem Toxicol,2013, 58:133-140.
28. Sanders L H, Paul K C, Howlett E H, et al. Base excision repair variants and pesticide exposure increase Parkinson’s disease risk[J]. Toxicol Sci, 2017, 158(1):188-198.
29. Li L R, Sydenham E, Chaudhary B. et al. Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis(review)[J].Cochrane Database Syst Rev,2012,(7):CD008084.
30. Wollin L, Maillet I, Quesniaux V,et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014, 349(2):209-220.
31. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2011, 365(12):1079-1087.
32. Dimitroulis I A. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis[J]. Respir Care, 2014, 59(9):1450-1455.
33. GONG Ping, LU ZhiDan, XING Jing, et al. Traditional Chinese medicine Xuebijing treatment is associated with decreased mortality risk of patients with moderate paraquat poisoning[J]. Plos One, 2015, 10(4):e0123504.
34. SHI XiaoFeng, ZHANG Yue, WANG YongQiang. Impact of Xuebijing and ulinastatin as assistance for hemoperfusion in treating acute paraquat poisoning[J]. Int J Clin Exp Med, 2015, 8(8):14018-14023.
35. LIU MingWei, SU MeiXian, ZHANG Wei, et al. Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats[J]. BMC Complement Altern Med, 2014, 14(1):498.
36. Tyagi N, Dash D, Singh R. Curcumin inhibits paraquat induced lung inflammation and fibrosis by extracellular matrix modifications in mouse model[J]. Inflammopharmacology, 2016, 24(6):335-345.
37. Punithavathi D, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats[J]. Br J Pharmacol, 2003, 139(7):1342-1350.
38. Mohammadi-Karakani A, Ghazi-Khansari M, Sotoudeh M. Lisinopril ameliorates paraquat-induced lung fibrosis[J]. Clin Chim Acta, 2006, 367(1-2):170-174.
39. HUANG Yang, YIN Wen, JIA Bin,et al. Protection of bone marrow mesenchymal stem cells from acute lung injury induced by paraquat poisoning[J]. Clin Toxicol, 2011, 49(4):298-302